Eligible Drug Costs Need Defining In Medicare Clinical Trial Policy, GSK Says: Drug Firms Recommend Revisions
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase I studies and public access to data generated by CMS-approved research under national coverage determinations.
You may also be interested in...
Tie Goes To The Nominee: Becerra Heads To Senate Floor
Without Republican support, Biden’s HHS nominee couldn’t get a majority in the Finance Committee, but that shouldn’t imperil his bid to become secretary of Health and Human Services.
AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.
Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.
Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: